HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

PLGA microparticles with zero-order release of the labile anti-Parkinson drug apomorphine.

Abstract
The treatment of patients suffering from advanced Parkinson's disease is highly challenging, because the efficacy of the "gold standard" levodopa declines with time. Co-administration of the dopamine receptor agonist apomorphine is beneficial, but difficult due to the poor oral bioavailability and short half-life of this drug. In order to overcome these restrictions, PLGA-based microparticles allowing for controlled parenteral delivery of this morphine derivative were prepared using (solid-in-)oil-in-water extraction/evaporation techniques. Particular attention was paid to minimize spontaneous oxidation of the labile drug and to optimize the key features of the microparticles, including encapsulation efficiency, initial burst release and particle size. Various formulation and processing parameters were adjusted in this respect. The systems were thoroughly characterized using SEM, EDX, DSC, laser diffraction, headspace-GC as well as in vitro drug release measurements in agitated flasks and flow-through cells. Importantly, apomorphine could effectively be protected against degradation during microparticle preparation and within the delivery systems upon exposure to phosphate buffer pH 7.4 (containing 0.2% ascorbic acid) at 37 °C: 90% intact drug was released at a constant rate during about 10d.
AuthorsC Regnier-Delplace, O Thillaye du Boullay, F Siepmann, B Martin-Vaca, N Degrave, P Demonchaux, O Jentzer, D Bourissou, J Siepmann
JournalInternational journal of pharmaceutics (Int J Pharm) Vol. 443 Issue 1-2 Pg. 68-79 (Feb 25 2013) ISSN: 1873-3476 [Electronic] Netherlands
PMID23313920 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 Elsevier B.V. All rights reserved.
Chemical References
  • Antiparkinson Agents
  • Drug Carriers
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Lactic Acid
  • Apomorphine
Topics
  • Antiparkinson Agents (administration & dosage, chemistry)
  • Apomorphine (administration & dosage, chemistry)
  • Calorimetry, Differential Scanning
  • Drug Carriers (chemistry)
  • Drug Compounding
  • Drug Stability
  • Freeze Drying
  • Hydrogen-Ion Concentration
  • Lactic Acid (chemistry)
  • Microscopy, Electron, Scanning
  • Particle Size
  • Polyglycolic Acid (chemistry)
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Solubility
  • Surface Properties
  • X-Ray Diffraction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: